Prudential PLC Acquires 36,159 Shares of Bristol Myers Squibb Company $BMY

by · The Markets Daily

Prudential PLC boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 8.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 463,306 shares of the biopharmaceutical company’s stock after acquiring an additional 36,159 shares during the quarter. Prudential PLC’s holdings in Bristol Myers Squibb were worth $20,895,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the period. Total Investment Management Inc. purchased a new position in Bristol Myers Squibb in the 2nd quarter worth about $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $40,000. Finally, Bank of Jackson Hole Trust grew its stake in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 810 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research analyst reports. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.00.

Read Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Stock Up 0.1%

NYSE:BMY opened at $59.02 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company’s 50 day moving average is $58.24 and its two-hundred day moving average is $51.40. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $120.18 billion, a PE ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the firm earned $1.67 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).